Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 10/20 | 0.62 |
| ▸ | RAB9A | P51151 | 10/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.54 |
| ▸ | RELA | Q04206 | 3/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048932 | 0.96 | NPC1 (0.67) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1466022 | 0.96 | NPC1 (0.67) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL22627409 | 0.94 | NPC1 (0.65) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL9419020 | 0.94 | NPC1 (0.65) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL21584068 | 0.91 | NPC1 (0.67) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL29793289 | 0.91 | NPC1 (0.67) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL27649495 | 0.89 | ALDH1A1 (0.56) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL19231579 | 0.84 | NPC1 (0.58) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL13928814 | 0.82 | NPC1 (0.56) | ALDH1A1NPC1RAB9AMAPTHSD17B1 | |
| SCHEMBL18637955 | 0.82 | MAPT (0.56) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| CN-119638680-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638681-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638682-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-116323598-B | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-111936471-B | Non-fused thiophene derivatives and uses thereof | 埃尼奥制药公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024024508-A1 | COMPOSITION, FILM, OPTICAL FILTER, SOLID STATE IMAGING DEVICE, IMAGE DISPLAY DEVICE, INFRARED RADIATION SENSOR, AND METHOD FOR PRODUCING CAMERA MODULE | 富士フイルム株式会社 | 2024-02-01 | — | — | WO | disclosed |
| WO-1999040091-A1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 1999-08-12 | — | — | WO | disclosed |
| WO-1996015100-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996015099-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-05-23 | — | — | WO | disclosed |
| US-4692447-A | HYPOTENSIVE, VASODILATOR, ANTITHROMBOTIC, ANTIAGGREGANT, CYTOPROTECTIVE | BOEHRINGER BIOCHEMIA ROBIN, S.P.A. (IT) | 1987-09-08 | — | — | US | disclosed |
| CN-85107017-A | Preparation three ring pyridazinones dihydro compounds and the method that contains the pharmaceutical composition of this compound | — | 1987-04-01 | — | — | CN | disclosed |
| US-4613611-A | HYPOGLYCEMIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0169443-A2 | Tricyclic dihydropyridazinones and pharmaceutical compositions contaning them | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1986-01-29 | — | — | EP | disclosed |
| EP-0039025-B1 | DERIVATIVES OF ARYL KETONES AS SENSITIZERS OF PHOTOPOLYMERIZABLE COMPOUNDS FOR THE VISIBLE SPECTRAL RANGE, AND PHOTOPOLYMERIZABLE COMPOSITIONS COMPRISING THE SAID SENSITIZERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-03-14 | — | — | EP | disclosed |
| US-4351893-A | TRIARYLIMIDAZOLE DIMER INITIATORS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-09-28 | — | — | US | disclosed |
| EP-0039025-A1 | Derivatives of aryl ketones as sensitizers of photopolymerizable compounds for the visible spectral range, and photopolymerizable compositions comprising the said sensitizers | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | ALDH1A1 4075/4885NPC1 1908/4885RAB9A 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.